Authors
Latest:
Unmet Needs of AML and Advice for Community OncologistsCourtney DiNardo, MD, concludes with discussing some challenges faced when treating patients with AML and shares some advice for community oncologists treating acute myeloid leukemia.
Latest:
Apa-RP Study Suggests Potential for Apalutamide and ADT in Prostate CancerVitaly Margulis, MD, discusses the key takeaways and next steps of the Apa-RP study of apalutamide plus androgen deprivation therapy in patients with high-risk localized prostate cancer.
Latest:
An Update on Current and Emergent Therapies for Essential ThrombocytosisThe therapeutic landscape for myeloproliferative neoplasms is shifting toward a goal of meaningful disease modification.
Latest:
Next Steps for Trastuzumab Emtansine After the KAMILLA TrialRachel Würstlein, MD, discusses the use of trastuzumab emtansine following the KAMILLA trial which evaluated the agent in patients with HER2-positive locally advanced or metastatic breast cancer who have brain metastases.
Latest:
About the Phase 3 SunRISe-5 Study of TAR-200Sima Porten, MD, MPH, discusses the rationale for the phase 3 SunRISe-5 study of TAR-200 in non-muscle invasive bladder cancer and unmet needs in this patient population.
Latest:
Graff on Using the Signatera Assay to Assess ctDNA in Early Breast CancerStephanie L. Graff, MD, discusses what a community oncologist should know about her presentation on the Signatera assay in patients with hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer after adjuvant abemaciclib and endocrine therapy.
Latest:
Treating the Patient With CML Who Is Pregnant or Trying to Become PregnantCareful management by a team of specialists is needed to balance disease control and fetal health in patients with CML who are pregnant or trying to become prengant.
Latest:
Williams on the Phase 3 SunRISe-2 Study of TAR-200/Cetrelimab in MIBCStephen Williams, MD, discusses the phase 3 SunRISe-2 study investigating TAR-200 plus cetrelimab in muscle-invasive bladder cancer being presented at the 2024 American Urological Association Annual Meeting.
Latest:
Using ctDNA in Stage II Colon CancerCristian Tomasetti, discusses the role of circulating tumor-DNA after surgery in patients with stage II colon cancer.
Latest:
Clinical Considerations with Axtilimab in R/R GVHDPanelists discuss how clinical considerations shape the use of axatilimab in relapsed or refractory graft-versus-host disease, addressing factors that influence its application and management in practice.
Latest:
Enhancing Patient-Centered Prostate Cancer Care CoordinationA discussion on streamlining patient care processes between urologists and medical oncologists while maintaining treatment continuity and minimizing disruptions for patients with prostate cancer.
Latest:
EP. 9A: The Rationale for CDK4/6 Inhibition in ES-SCLC and Updates on Trilaciclib Clinical Trial DataIn the fifth interview of the series, medical oncologist and hematologist Dr. Jerome H. Goldschmidt from Blue Ridge Cancer Care elaborates on the rationale for use of CDK4/6 inhibitors such as trilaciclib for prevention of chemotherapy-induced myelosuppression (CIM) in extensive-stage small cell lung cancer (ES-SCLC), and touches on recently presented data on trilaciclib.
Latest:
Risk-Adapted Study Enhances Response to IDH2-Targeted Therapy for AMLSheng F. Cai, MD, PhD, discusses the results of the BEAT AML master trial in patients with acute myeloid leukemia.
Latest:
DuMontier Discusses Frailty in Newly Diagnosed Multiple MyelomaClark DuMontier, MD, discusses the main takeaways from his presentation on treatment intensity and frailty in newly diagnosed patients with multiple myeloma given at the 20th International Myeloma Society Annual Meeting.
Latest:
Bispecific Antibodies Look Promising in Follicular LymphomaThe use of bispecific antibodies has the potential to revolutionize the management of FL.
Latest:
Expert Highlights Immunotherapy Advances in Lung Cancer Treatment LandscapeDavid M. Waterhouse, MD, MPH, shares advice with community oncologists treating patients with lung cancer.
Latest:
First-Line ICI-Based Combinations for mRCC With Sarcomatoid FeaturesRenal cancer experts conclude their discussion by examining first-line immune checkpoint inhibitor-based combination therapies for metastatic renal cell carcinoma with sarcomatoid features, and offer their final insights on the current state and future directions of RCC treatment.
Latest:
Kantarjian on Solutions for Oncology Drug ShortagesAccording to Hagop M. Kantarjian, MD, there are options for limited oncology drug shortages that require multi-sector involvement.
Latest:
Olaparib Plus Abiraterone/Prednisone Improves Survival in mCRPCA promising new treatment combination of frontline olaparib plus abiraterone/prednisone has emerged for advanced prostate cancer with specific genetic alterations.
Latest:
About the Phase 1/2 Study of IGV-001 in GlioblastomaDeric Park, MD, discusses a phase 1/2 study of IGV-001, a novel treatment for glioblastoma.
Latest:
Chemotherapy-Free Regimens Gain Ground in Older Patients With ALLWhile there have been exciting advancements in the treatment of B-cell acute lymphoblastic leukemia over the course of the past decade, the treatment of older adults remains a challenge.
Latest:
Building on the Success of Osimertinib in EGFR-Mutated NSCLCSuresh S. Ramalingam, MD, FACP, FASCO, discusses the background and next steps of the LAURA study which evaluated osimertinib for the treatment of patients with unresectable stage III non–small cell lung cancer with EGFR mutations.
Latest:
Incorporating Immunotherapy Into Hodgkin Lymphoma Treatment StrategiesStephen M. Ansell, MD, PhD, discusses how immunotherapy is being integrated into treatment for patients with advanced stage Hodgkin lymphoma.
Latest:
Melanoma Monday: A Review of the MSLT-II Trial and Completion Lymph Node DissectionKatherine E. Poruk, MD, reviews the use of complete axillary lymph node dissection and the Multicenter Selective Lymphadenectomy Trial II for Melanoma Monday.
Latest:
Utilizing Interpretable AI to Distinguish prePMF From ETAndrew Srisuwananukorn, MD, discusses the main findings from research of an artificial intelligence-powered machine learning algorithm which evaluated digital whole-slide images of diagnostic bone marrow biopsies and accurately differentiated prefibrotic primary myelofibrosis from essential thrombocythemia.
Latest:
Investigating Prognostic Markers for OS With LuPSMA Treatment in mCRPCAndrei Gafita, MD, discusses the overall survival in patients with metastatic castration-resistant prostate cancer who received 177Lutetium-prostate-specific membrane antigen radionuclide treatment.
Latest:
Expanding 177Lutetium-PSMA-617 Use in the CommunityTraining at a major academic center offers firsthand exposure to groundbreaking 177Lu-PSMA-617 treatment for advanced prostate cancer.
Latest:
Choosing the Optimal Treatment for Patients With Prostate CancerNasir Chaudry, MD, discusses treatment decisions for patients with prostate cancer and the importance of individualized treatment based on the specific case and patient preferences.
Latest:
Efficacy and Safety: Brexu-cel's Impact on CNS Response in B-ALLIbrahim N. Muhsen, MD, discusses the findings and key takeaways from his presentation given at the 2024 Tandem Meeting.
